# OnCo record cll13-gaia (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/cll13-gaia/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "cll13-gaia", "NCT02950051" ;
  schema:name "CLL13 / GAIA"@en ;
  schema:description "In fit patients, one year of venetoclax plus obinutuzumab (with or without ibrutinib) clearly beat the old chemotherapy standard."@en ;
  schema:url <https://onco.cc/trials/cll13-gaia/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02950051> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2016-12-13" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-treatment-naive/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/ibrutinib/> ;
  onco:companies <https://onco.cc/companies/german-cll-study-group/> ;
  onco:terms <https://onco.cc/terms/ighv-status/>, <https://onco.cc/terms/mrd-negative-cr/> ;
  onco:people <https://onco.cc/people/barbara-eichhorst/>, <https://onco.cc/people/michael-hallek/> .